卡培他滨、奥沙利铂联合重组人血管内皮抑素在老年晚期大肠癌治疗中的临床疗效分析  

Clinical study of capecitabine、oxaliplatin combined Recombinant Human Endostatin for advanced colorectal cancer

作　　者：张箐茹[1] 陆梅[1] 

机构地区：[1]辽宁省肿瘤医院大肠科手术室,辽宁沈阳110042

出　　处：《四川医学》2013年第2期234-235,共2页Sichuan Medical Journal

摘　　要：目的前瞻性观察卡培他滨、奥沙利铂联合重组人血管内皮抑素在老年晚期大肠癌治疗的有效性和安全性。方法 100例老年晚期大肠癌患者随即分为治疗组和对照组各50例,对照组采用卡培他滨、奥沙利铂进行化疗,治疗组在此基础上增加重组人血管内皮抑素进行治疗,观察两组患者疗效及不良反应。结果治疗组完全缓解(CR)比例明显高于对照组,而进展(PD)比较明显低于对照组,差异有统计学意义(P<0.01),并且对照组恶心呕吐,末梢神经炎发生比例明显低于对照组,差异有统计学意义(P<0.05)。结论卡培他滨、奥沙利铂联合重组人血管内皮抑素治疗大肠癌疗效好,毒性低,安全性和耐受性均较好,值得临床推广应用。Objective To observe prospectively and systematically the effect and safety of apecitabine、oxaliplatin combined Recombinant Human EndostatinInjectionchemotherapy for advanced colorectal cancer chemotherapy for advanced colorectal cancer.Methods 100 cases of elderly patients with advanced colorectal cancer were randomly divided into treatment group and control group,50 cases in each group,the control group using capecitabine,oxaliplatin chemotherapy,treatment group on the basis of increasing of Recombinant Human Endostatin treatment,observe two groups of patients curative effect and adverse reaction.Results The treatment group was significantly higher than in CR in control group,but PD was significantly lower than the control group,the difference is statistically significant（P〈0.01）,and a control group of nausea and vomiting,peripheral neuritis incidence rate was significantly lower than the control group,the difference was statistically significant（P〈0.05）.Conclusion Capecitabine,oxaliplatin combined with recombinant human endostatin therapy colorectal cancer has good curative effect,low toxicity and tolerable.It is worth of further clinical observation

关 键 词：大肠癌 卡培他滨 奥沙利铂 重组人血管内皮抑素 

分 类 号：R735.34[医药卫生—肿瘤]